A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85% coverage when vaccinated 4 weeks before birth
- Antibodies from the mother transferred through the placenta safeguard newborns from birth
- Coverage achievable with 2-week gap before premature birth
- Vaccination in the third trimester still offers meaningful protection for infants
Strong evidence from current research
The efficacy of the pregnancy RSV vaccine has been demonstrated through a thorough investigation conducted across England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable information of the vaccine’s real-world impact. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across varied populations and settings.
The results present a striking picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This marked difference underscores the vaccine’s critical role in protecting against serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research examined birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology assessed practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine works when given across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the risks
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.
The infection produces deep inflammation in the lungs and airways, making it dangerously difficult for infected babies to breathe and feed adequately. Parents commonly see their babies struggling visibly, their chests heaving as they try to pull sufficient oxygen into their compromised lungs. Whilst the majority of babies improve through supportive care, a modest yet notable number die from RSV complications annually, making immunisation programmes a vital health service imperative for defending the youngest and most vulnerable individuals in the population.
- RSV triggers inflammation in lungs, leading to severe breathing difficulties in infants
- Nearly 50% of newborns catch the infection in their first few months of life
- Symptoms range from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- A small number of babies die from RSV related complications each year in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have emphasised the importance of pregnant women getting their jab at the best time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns benefit from the most robust immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to maximise the antibodies transferred to their babies via the placenta.
The messaging from health authorities stays clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV represents the highest danger of severe infection.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and availability of the jab. These geographical variations reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the national data shows robust and reliable protection irrespective of geographical location.
- NHS trusts deploying varied communication campaigns to engage with pregnant women
- Geographic variations in vaccine uptake rates in different parts of England require targeted improvement
- Community health services adapting programmes to align with specific population needs
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness provides real advantages for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the rollout of this protective measure, the 80% reduction in admissions equates to thousands of infants protected against severe infection. Parents no more face the upsetting situation of seeing their babies gasping for air or struggle to eat, symptoms that characterise severe RSV infections. The vaccine has fundamentally shifted the picture of neonatal breathing health, providing expectant mothers a active means to shield their most vulnerable children during those critical early months.
For families like that of Malachi, whose acute RSV infection resulted in profound brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s advocacy for the jab highlights the life-altering consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to pregnant women in their final trimester, converting what was once an inevitable seasonal threat into a controllable health concern.